Disease Domain | Count |
---|---|
Immune System Diseases | 6 |
Neoplasms | 6 |
Hemic and Lymphatic Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 6 |
Recombinant protein | 4 |
Small molecule drug | 4 |
Biological products | 2 |
Interleukins | 1 |
Target |
Mechanism IL1R1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TYK2 inhibitors |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Aug 2022 |
Sponsor / Collaborator |
Start Date25 Oct 2021 |
Sponsor / Collaborator |
Start Date24 Jun 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
UA020 | Multiple Myeloma More | Phase 2 Clinical |
Recombinant human interleukin-1 receptor antagonist(General Regeneratives) ( IL1R1 ) | Arthritis, Gouty More | Phase 2 |
UA010 | Anaphylaxis More | Phase 1 |
UA011 | Solid tumor More | Phase 1 |
UA-008 | Arthritis More | Phase 1 |